Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...

As FDA seeks to rehire some fired employees, Donald Trump threatens to enact tariffs on pharma companies unless they reshore manufacturing; another lawsuit hits the complex GLP-1 compounding space as ...

Short-selling is an interesting part of the stock market that can be dangerous and even controversial. Investors selling ...

“As time goes on, they’re more willing to share their story because they get so many compliments,” she said. “The person who is next to them says, ‘Tell me your secret,’ and they may whisper my name ...

Eli Lilly & Co. said Tuesday it's cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will also ...

This writer noticed that UK stock investors have been buying an obscure share that fell 26% yesterday but is still up nearly ...

The Food and Drug Administration has determined that the shortage of Wegovy® (semaglutide) and Ozempic® (semaglutide) is resolved.

The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...

A group that represents pharmacies that have been producing off-brand versions of GLP-1 weight-loss drugs just filed another ...

Tennessee Attorney General Jonathan Skrmetti led a 38-state bipartisan coalition last week requesting that the Food and Drug ...

A trade group representing compounding pharmacies has filed a lawsuit against the Food and Drug Administration (FDA) for ...

Compounding lobby group sues FDA over semaglutide shortage list removal, arguing Novo Nordisk's Ozempic and Wegovy remain in ...